NCPA members speak at annual FDA listening session on compounding

NCPA members Sara Hover and Derrick Waller represented NCPA at FDA’s annual listening session on compounding. Hover and Waller each issued five-minute statements taken from NCPA’s larger written statement for the record, which NCPA submitted to the FDA ahead of time. Together, Hover and Waller discussed concerns with desiccated thyroid extract being labelled as a biological product, patient access to compounded bioidentical hormone therapy, and drug shortages, among other concerns. Representatives from the Alliance for Pharmacy Compounding, the American Pharmacists Association, the American Society of Health System Pharmacists, and PCCA also spoke at the listening session.